Park et al. demonstrated that breast cancer type 1 susceptibility protein (BRCA1) is a coactivator of the AR and together with the P160 co-activators may modulate AR signaling through direct interaction with the AF1 domain in both breast and prostate cancer. Here, AR is linked to prostate carcinoma.